

September 19, 2016



Actinium Pharmaceuticals to Present at Ladenburg Thalmann 2nd Annual Healthcare Conference

- Actinium to Present on Tuesday, September 27, 2016 at 1:00 PM ET

- Management Will be Available for 1-on-1 Meetings with Conference Attendees

NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will be presenting at the Ladenburg Thalmann 2nd Annual Healthcare Conference being held on Tuesday, September 27, 2016 at the Sofitel Hotel in New York, New York. Details regarding Actinium's presentation are below:

Event: Ladenburg Thalmann 2nd Annual Healthcare Conference

Location: Sofitel Hotel, New York, New York

Presentation Time: 1:00 PM ET

Room: Montmartre, Track 5

Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting with management please contact Steve O'Loughlin, Vice President, Finance and Corporate Development at soloughlin@actiniumpharma.com.

Actinium's presentation can be viewed live via webcast through the following link <http://wsw.com/webcast/ladenburg2/atnm>. The presentation will be archived and available for playback via the investor relations page of Actinium's website <http://ir.actiniumpharma.com/ir-calendar>.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable

complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com



Source: Actinium Pharmaceuticals